Kite Pharma

December 20, 2016December 20, 2016

Kite and Vitruvian Developing Platform to Safely Deliver T-cell Therapies at Commercial Scale

News

Kite Pharma and Vitruvian Networks announced a strategic collaboration to create a software solution that will help to support commercial availability of T-cell therapies. The companies will jointly design and develop a ... Read more

December 19, 2016

Kite’s CAR T-cell Therapy Shows Great Promise in Non-Hodgkin’s Lymphoma Patients

News

Car T-cell immunotherapy has shown great promise in non-Hodgkin’s lymphoma patients, according to data from a multicenter Phase 1/2 trial, presented at the 58th American Society of Hematology (ASH) Annual Meeting ... Read more

November 8, 2016

Trial Data on Kite’s Lead Candidate for B-Cell Lymphomas to Be Presented at Meeting

News

Kite Pharma will present data from multiple clinical trials of KTE-C19, the company’s lead candidate CAR-T cell therapy for B-cell lymphomas and leukemias at the American Society of Hematology (ASH) ... Read more

October 17, 2016

Kite Appoints European Head to Prepare for Potential Launch of Lead Lymphoma Therapy

News

Kite Pharma has appointed Chris Nowers as its new Head of Europe to oversee European commercial operations, raise awareness of Kite’s pipeline portfolio of CAR and T-cell receptor (TCR) therapy ... Read more

October 12, 2016October 12, 2016

Phase 1b/2 Trial of Combo Therapy for Diffuse Large B-cell Lymphoma Gets Underway

News

Kite Pharma has enrolled the first patient in a Phase 1b/2 study evaluating the safety and efficacy of KTE-C19, a CAR T-cell therapy, in combination with Genentech’s anti-PD-L1 immunotherapy atezolizumab, for the ... Read more

September 29, 2016

Interim Analysis Shows Promise for KTE-C19 in Treating Aggressive Non-Hodgkin Lymphomas

News

Kite Pharma recently reported positive data from an interim analysis of ZUMA-1, a clinical trial assessing the safety and efficacy of KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL). KTE-C19 is an ... Read more

June 2, 2016June 2, 2016

Kite Pharma Moves Forward with KTE-C19 for Chemorefractory Diffuse Large B-Cell Lymphoma

News

Kite Pharma, Inc., a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, is moving forward with the company’s KTE-C19, an experimental therapy currently in a pivotal trial ... Read more

August 18, 2015August 23, 2016

Kite Pharma Updates KTE-C19 Clinical Trial progress, On Track To Advance To Pivotal Phase 2

News

Santa Monica, California, based Kite Pharma, Inc. (Kite) on Monday provided in a Conference Call and Webcast, an updated progress report from the company’s ongoing Phase 1/2 clinical trial of ... Read more